{"id":24616,"date":"2025-04-13T17:42:16","date_gmt":"2025-04-13T17:42:16","guid":{"rendered":"https:\/\/researchchemicalstore.eu\/?post_type=product&p=24616"},"modified":"2025-10-21T11:28:22","modified_gmt":"2025-10-21T11:28:22","slug":"2c-d-10-mg-pellets","status":"publish","type":"product","link":"https:\/\/researchchemicalstore.eu\/nb\/produkt\/2c-d-10-mg-pellets\/","title":{"rendered":"2C-D 10 MG-pellets"},"content":{"rendered":"

2C-D 10mg Pellets \u2013 Precision-Dosed Research Substance<\/span><\/span><\/strong><\/h2>\n

Produktbeskrivelse<\/span><\/span><\/strong><\/h3>\n

2C-D, Our <\/span><\/span>2C-D 10mg pellets<\/span><\/span><\/strong> \u00a0are a precisely dosed research formulation of this phenylethylamine derivative, specifically developed for\u00a0 <\/span><\/span>vitenskapelig forskning p\u00e5 serotonerge systemer<\/span><\/span><\/strong> . Hver pellet inneholder n\u00f8yaktig\u00a0 <\/span><\/span>10mg of 2,5-dimethoxy-4-methylphenylethylamine (2C-D)<\/span><\/span><\/strong> \u00a0in a pharmaceutical tablet format for reproducible administration.<\/span><\/span><\/p>\n

Viktige funksjoner<\/span><\/span><\/strong><\/h3>\n

\u2714\u00a0Exactly 10mg active ingredient per unit <\/span><\/span><\/strong>
\n\u2714\u00a0Optimized composition<\/span><\/span><\/strong> \u00a0for oral bioavailability <\/span><\/span>
\n\u2714\u00a0N\u00f8ytral smak<\/span><\/span><\/strong> \u00a0for komfort ved dyrefors\u00f8k <\/span><\/span>
\n\u2714\u00a0GMP produced<\/span><\/span><\/strong> \u00a0under controlled conditions<\/span><\/span><\/p>\n

\n

Sammendrag av laboratorierapport (COA)<\/span><\/span><\/strong><\/h2>\n

*Batch #2CD-NL1224 | Tested by PsychoTech Analytics* <\/span><\/span>
\n\u2714\u00a010.2mg \u00b10.15mg per pellet<\/span><\/span><\/strong> \u00a0(UV spectroscopy) <\/span><\/span>
\n\u2714\u00a098.7% chemical purity<\/span><\/span><\/strong> \u00a0(HPLC) <\/span><\/span>
\n\u2714\u00a0No detectable heavy metals <\/span><\/span><\/strong>
\n\u2714\u00a0Mikrobiologisk trygg<\/span><\/span><\/strong> \u00a0(meets EP 2.6.13)<\/span><\/span><\/p>\n

\n

Anbefalte forskningsform\u00e5l<\/span><\/span><\/strong><\/h2>\n

1. Nevropsykiatrisk unders\u00f8kelse<\/span><\/span><\/strong><\/h3>\n